MODDERN Cures Act of 2011
Latest action · Dec 2, 2011 Referred to the Subcommittee on Intellectual Property, Competition and the Internet.
Progress
Where this bill reached, and when. A stage with no date was not reached; one that failed a vote and later carried shows the date it carried.
- IntroducedNov 18, 2011
- Passed HouseNot reached
- Passed SenateNot reached
- To the PresidentNot reached
- Became lawNot reached
Summary
Modernizing Our Drug & Diagnostics Evaluation and Regulatory Network Cures Act of 2011 or the MODDERN Cures Act of 2011 - Requires the Secretary of Health and Human Services (HHS) to: (1) establish the Advanced Diagnostics Education Council to recommend standard terms and definitions related to innovative diagnostics for use by patients, physicians, health care providers, payers, and policy makers.; and (2) publish a guide regarding such terms and definitions.
Sets forth additional factors for the Secretary to consider in determining the payment amount for new clinical diagnostic laboratory tests under gap filling procedures which are used when no comparable existing test is available.
Extends the exclusivity period for a drug or biological product if the diagnostic test related to such drug has been determined by the Secretary to have been developed by, or with the participation of, the manufacturer or sponsor of the drug or biological product, and use of the diagnostic tests provides for or improves: (1) the identification of a patient population for the drug or biological product; or (2) the determination of the most appropriate treatment option for a patient population with the drug or biological product.
Establishes a dormant therapy designation for drugs or biological products that address unmet medical needs. Gives such a drug or biological product 15 years of data exclusivity under which no drug can be approved by relying on the approval or licensure of the dormant therapy.
Cosponsors 48
Members who signed on, in the order they did. Signatures ran from Dec 2, 2011 to Nov 29, 2012.
| Seat | Cosponsor | Signed on | |
|---|---|---|---|
| D-WA | Jay Inslee | Dec 2, 2011 | |
| R-IA | Tom Latham | Dec 2, 2011 | |
| D-MA | Barney Frank | Dec 12, 2011 | |
| R-IL | Joe Walsh | Dec 12, 2011 | |
| R-IL | Randy Hultgren | Dec 12, 2011 | |
| D-VA | James P. Moran | Feb 6, 2012 | |
| R-KY | Brett Guthrie | Feb 14, 2012 | |
| R-IL | Peter J. Roskam | Mar 7, 2012 | |
| D-CA | Barbara Lee | Apr 16, 2012 | |
| D-IL | Jesse L. Jackson, Jr. | May 9, 2012 | |
| D-FL | Corrine Brown | May 16, 2012 | |
| D-DC | Eleanor Holmes Norton | May 16, 2012 | |
| R-OR | Greg Walden | May 16, 2012 | |
| D-PA | Mark S. Critz | May 16, 2012 | |
| R-NY | Peter T. King | May 16, 2012 |
Committees 3
Where it was sent and what each committee and subcommittee did with it, in order.
| Chamber | Committee | What it did |
|---|---|---|
| House | Energy and Commerce Committee | Referred Nov 18, 2011 |
| Health Subcommittee | Referred Nov 18, 2011 | |
| House | Ways and Means Committee | Referred Nov 18, 2011 |
| Health Subcommittee | Referred Nov 22, 2011 | |
| House | Judiciary Committee | Referred Nov 18, 2011 |
| Over-Criminalization Task Force Subcommittee | Referred Dec 2, 2011 |
Actions 5
Everything that happened, newest first.
- Dec 2, 2011Referred to the Subcommittee on Intellectual Property, Competition and the Internet.
- Nov 22, 2011Referred to the Subcommittee on Health.
- Nov 18, 2011Introduced in House
- Nov 18, 2011Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, and the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- Nov 18, 2011Referred to the Subcommittee on Health.
Research
What has been written about this bill: committee reports, cost estimates, the sponsor’s authority statement, printed hearings and the Congressional Research Service’s work.
Constitutional authority
The sponsor’s statement, as printed in the page H7892.
CRS reports 1
Congressional Research Service work that CRS links to this bill or the law it became, newest first.
Cite it 1
Products on other subjects that cite it, usually among other measures.
| Product | Title | Kind | Published |
|---|---|---|---|
| R44032 | Patents and Regulatory Exclusivities: Issues in Pharmaceutical Innovation and Competition Archived | Report | May 1, 2015 |
Related bills 1
Companion bills and other measures the record links to this one.
| Bill | Title | Relationship | Latest action |
|---|---|---|---|
| HR 6446 | Improving Diagnostic Innovations Act of 2012 | Related bill | Sep 26, 2012 |
Titles 3
Every title it has carried, official and short, at each stage.
- Official Title as Introduced
- To promote the development of meaningful treatments for patients.
- Short Titles as Introduced
- MODDERN Cures Act of 2011
- Modernizing Our Drug & Diagnostics Evaluation and Regulatory Network Cures Act of 2011
Subjects
Assigned by the Library of Congress. Policy area: Health.
- Administrative law and regulatory procedures
- Advisory bodies
- Department of Health and Human Services
- Drug safety, medical device, and laboratory regulation
- Drug therapy
- Executive agency funding and structure
- Government information and archives
- Health
- Health information and medical records
- Intellectual property
- Medical research
- Medical tests and diagnostic methods
- Medicare
- Research and development
Text 1
Each version as it was printed, newest first.
- Nov 18, 2011Introduced in House
Everything here is as published by Congress: the summary is the Congressional Research Service's, the action wording is the clerks', and the subjects are the Library of Congress's. How far it got is read from the actions themselves, taking the most recent one of each kind, so a bill that failed a vote and later passed is shown as having passed. Records come from this bill on Congress.gov and govinfo.gov; cost estimates are the Congressional Budget Office's, and the hearings are the printed hearings GovInfo publishes, which can appear months after the hearing.